Zotiraciclib Uses, Dosage, Side Effects and more
Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).
| Trade Name | Zotiraciclib |
| Generic | Zotiraciclib |
| Type | |
| Formula | C23H24N4O |
| Weight | Average: 372.472 Monoisotopic: 372.195011409 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
